CytomX Therapeutics (NASDAQ:CTMX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

A number of other research firms also recently weighed in on CTMX. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Cantor Fitzgerald began coverage on CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price for the company. Cowen reaffirmed an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. Oppenheimer reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Finally, Bank of America upped their target price on CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $31.88.

Shares of CytomX Therapeutics (NASDAQ:CTMX) traded up $0.36 on Friday, reaching $21.06. The company’s stock had a trading volume of 449,116 shares, compared to its average volume of 337,091. CytomX Therapeutics has a 52-week low of $10.03 and a 52-week high of $24.67.

In related news, CFO Debanjan Ray sold 2,500 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $20.00, for a total value of $50,000.00. Following the sale, the chief financial officer now owns 12,126 shares in the company, valued at $242,520. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Frederick W. Gluck sold 5,000 shares of the stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $17.30, for a total value of $86,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 156,169 shares of company stock worth $3,488,563. Company insiders own 4.70% of the company’s stock.

Several hedge funds have recently modified their holdings of CTMX. Alliancebernstein L.P. purchased a new stake in shares of CytomX Therapeutics in the first quarter worth $598,000. Vanguard Group Inc. increased its stake in CytomX Therapeutics by 3.5% in the first quarter. Vanguard Group Inc. now owns 823,531 shares of the biotechnology company’s stock valued at $14,223,000 after acquiring an additional 27,532 shares during the last quarter. Geode Capital Management LLC increased its stake in CytomX Therapeutics by 8.9% in the first quarter. Geode Capital Management LLC now owns 208,710 shares of the biotechnology company’s stock valued at $3,604,000 after acquiring an additional 16,991 shares during the last quarter. Renaissance Technologies LLC increased its stake in CytomX Therapeutics by 157.5% in the first quarter. Renaissance Technologies LLC now owns 234,800 shares of the biotechnology company’s stock valued at $4,055,000 after acquiring an additional 143,600 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in CytomX Therapeutics by 5.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 100,091 shares of the biotechnology company’s stock valued at $1,729,000 after acquiring an additional 4,959 shares during the last quarter. Institutional investors own 63.28% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/cytomx-therapeutics-ctmx-downgraded-by-valuengine.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.